$BRKR

BRUKER CORP

Bruker develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions for customers in life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics and nanotechnology. Its products help users detect, measure and visualize samples at microscopic, molecular and cellular levels. Bruker is headquartered in Billerica, Massachusetts, and maintains technical and manufacturing centers in Europe and North America, with sales offices worldwide. Bruker operates four reportable segments: BSI BioSpin, BSI CALID, BSI NANO and Bruker Energy & Supercon Technologies. Its offerings include magnetic resonance, mass spectrometry, chromatography, X-ray, microscopy, metrology and molecular spectroscopy instruments, as well as diagnostic tests, software, automation and lifecycle services. Customers include academic and government research facilities, pharmaceutical and biotechnology companies, hospitals, industrial businesses and clinical laboratories. Bruker makes money by selling instruments, diagnostic products and related software and services.

0
2
0

No SEC Form 4 filings for $BRKR in the last 30 days.

See all $BRKR insider activity →
Low

Bruker appoints Eicke Latz to Board of Directors

Bruker Corp. (BRKR) appointed Eicke Latz to its Board of Directors, effective January 1, 2027. Latz will serve until the 2029 Annual Meeting of Stockholders, with committee assignments and compensation to be determined.

BRUKER CORP (BRKR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

BRUKER CORP (BRKR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Professor Eicke Latz has co-founded five biotechnology companies, including IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics, and Beren Therapeutics. His entrepreneurial efforts have focused on translating cutting-edge discoveries in innate i

Bruker Recasts Historical Results for Four-Segment Structure

Bruker Corp. (BRKR) reorganized its reportable segments effective July 1, 2026, and provided recast historical financial information. The four new segments are BSI BIOS, BMID, BSI NANO, and BEST. The realignment did not affect historical consolidated results, financial position, or cash flows. Bruker supplied recast segment data for 2024–2026 reporting periods to align with the new structure.

BRKR sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BRKR (BRUKER CORP). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.

Recent BRKR coverage spans financial news, corporate actions and earnings.

What's driving BRKR

AlphAI scores every news story that mentions BRKR with an AI model for sentiment and relevance, and aggregates insider trades from BRUKER CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $BRKR

Score
$BRKRLowExec change· appointed

BRUKER CORP (BRKR): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

BRUKER CORP (BRKR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Professor Eicke Latz has co-founded five biotechnology companies, including IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics, and Beren Therapeutics. His entrepreneurial efforts have focused on translating cutting-edge discoveries in innate i

Bruker Recasts Historical Results for Four-Segment Structure

Bruker Corp. (BRKR) reorganized its reportable segments effective July 1, 2026, and provided recast historical financial information. The four new segments are BSI BIOS, BMID, BSI NANO, and BEST. The realignment did not affect historical consolidated results, financial position, or cash flows. Bruker supplied recast segment data for 2024–2026 reporting periods to align with the new structure.

Bruker Scientific Instruments BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection Bruker Energy & Supercon Technologies…

BRUKER CORP (BRKR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 As Reported As Recast Bruker Scientific Instruments ("BSI") BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection ("BSI CALID") BSI NANO Bruker Energy & Supercon Technologies ("BEST") Corporate Total BSI Biosystems ("BIOS") BSI Microb

Bruker: Q3 Earnings Snapshot

Bruker Corp. (BRKR) reported a Q3 loss of $111.8M, or 81 cents per share, but adjusted earnings of 56 cents per share, exceeding analyst expectations of 42 cents. Revenue was $874M. The company forecasts full-year earnings of $2.10-$2.15 per share and revenue of $3.52B-$3.56B. BRKR shares are up 20% YTD and 46% over the past year.

$BRKRLowDividend· regular · $3.9844

The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A…

BRUKER CORP (BRKR) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share, of $3.9844 per share. The dividend was declared on October 29, 2026, and is

Bruker Jumps 6.3% Amid Sector-Wide Rally

Bruker Corporation's stock rose 6.3% to $59.45 on Wednesday, part of a broader sector-wide rally. Peers TXG, 1521.HK, ADPT, and AVTR also saw gains of 3.7% to 13.3%. The move was driven by sector rotation and institutional interest, with no company-specific news. Bruker's trading volume reached 597,428 shares, adding value to its $9.1 billion market cap.

Related tickers